-
DE
Urothelial protection therapy safeguards the bladder lining from toxic substances, especially during chemotherapy. Learn about its use, mechanism, and benefits.
Urothelial protection therapy safeguards the bladder lining from toxic substances, especially during chemotherapy. Learn about its use, mechanism, and benefits.
Urothelial protection therapy refers to medical measures designed to protect the urothelium – the specialized mucous membrane lining the urinary bladder, ureters, and urethra – from harmful substances. This therapy is most commonly used alongside specific chemotherapy regimens that produce toxic metabolites capable of severely damaging the bladder lining.
The primary indication for urothelial protection therapy is chemotherapy involving oxazaphosphorines, particularly the agents cyclophosphamide and ifosfamide. When metabolized in the body, these drugs produce a toxic byproduct called acrolein, which is excreted through the urine and can cause severe irritation and inflammation of the bladder mucosa.
The most widely used agent in urothelial protection therapy is Mesna (sodium 2-mercaptoethane sulfonate). Mesna is administered intravenously or orally and is rapidly converted to its active form in the kidneys. In the urine, Mesna binds to the toxic metabolite acrolein, neutralizing it before it can damage the urothelium.
Importantly, Mesna acts exclusively within the urinary tract and does not interfere with the antitumor activity of the chemotherapy in the rest of the body, making it a well-tolerated and targeted protective agent.
The dosage of Mesna is calculated based on the dose of the chemotherapy agent used and is determined individually by the treating physician. It is typically administered at defined time points before, during, and after chemotherapy to ensure continuous protection of the urothelium.
Mesna is generally well tolerated. Possible but uncommon side effects include:
Because Mesna acts specifically within the urinary tract, systemic side effects are comparatively minor. Most adverse effects experienced by patients during chemotherapy are attributable to the chemotherapy agents themselves rather than to Mesna.
Without urothelial protection therapy, oxazaphosphorine-based chemotherapy carries a significant risk of causing hemorrhagic cystitis – a serious condition involving inflammation of the bladder lining with heavy bleeding, pain, and potentially permanent bladder damage. Urothelial protection therapy has substantially reduced this complication, enabling the safe administration of highly effective cancer treatments.
For Healthy Oral Flora & Dental Care
Formulated lozenges with Dentalac®, lactic acid bacteria, and Lactoferrin CLN®
For Healthy Oral Flora & Dental Care
Formulated lozenges with Dentalac®, lactic acid bacteria, and Lactoferrin CLN®
For your universal protection
As one of the most valuable proteins in the body, lactoferrin is a natural component of the immune system.
For your iron balance
Specially formulated for your iron balance with plant-based curry leaf iron, Lactoferrin CLN®, and natural Vitamin C from rose hips.